Login to Your Account

Galapagos investors get jittery on GLPG634 delay, GLPG974 failure

By Cormac Sheridan
Staff Writer

Tuesday, June 17, 2014
Galapagos NV gave its investors some wobbles during its R&D day in New York Tuesday, revealing that its first-in-class, free fatty acid receptor 2 (FFA2) inhibitor, GLPG974, failed to demonstrate clinical benefit in ulcerative colitis and that recruitment delays will push back top-line data from two phase IIb trials of selective JAK1 inhibitor GLPG634 in rheumatoid arthritis patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription